Resveratrol has been shown to protect against HFHS-induced decreases in hepatic LDLR and SR-BI gene and protein expressions, providing new insights into its pharmacological targets in MASLD prevention [65]. Here, LDLR is linked to metabolic dysfunction-associated steatotic liver disease.